MedDataX Logo

Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

NCT ID: NCT00316732

Last Updated: 2017-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

173 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-10-25

Study Completion Date

2006-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Hyperplasia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Avodart IPSS BPH dutasteride EQ-5D Observational

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPSS Questionnaire

Intervention Type PROCEDURE

EQ-5D Questionnaire

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IPSS Questionnaire

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
* Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
* Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Exeter, Devon, United Kingdom

Site Status

GSK Investigational Site

Plymouth, Devon, United Kingdom

Site Status

GSK Investigational Site

Colchester, Essex, United Kingdom

Site Status

GSK Investigational Site

Stevenage, Hertfordshire, United Kingdom

Site Status

GSK Investigational Site

Manchester, Lancashire, United Kingdom

Site Status

GSK Investigational Site

Manchester, Lancashire, United Kingdom

Site Status

GSK Investigational Site

Leicester, Leicestershire, United Kingdom

Site Status

GSK Investigational Site

Leytonstone, London, United Kingdom

Site Status

GSK Investigational Site

Enfield, Middlesex, United Kingdom

Site Status

GSK Investigational Site

Nottingham, Nottinghamshire, United Kingdom

Site Status

GSK Investigational Site

Tauton, Somerset, United Kingdom

Site Status

GSK Investigational Site

Sunderland, Tyne & Wear, United Kingdom

Site Status

GSK Investigational Site

Sutton Coldfield, West Midlands, United Kingdom

Site Status

GSK Investigational Site

Birmingham, , United Kingdom

Site Status

GSK Investigational Site

Bradford, , United Kingdom

Site Status

GSK Investigational Site

Bradford, , United Kingdom

Site Status

GSK Investigational Site

Bristol, , United Kingdom

Site Status

GSK Investigational Site

East Kilbride, , United Kingdom

Site Status

GSK Investigational Site

Hull, , United Kingdom

Site Status

GSK Investigational Site

Ilkeston, Derbyshire, , United Kingdom

Site Status

GSK Investigational Site

Leeds, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

Sheffield, , United Kingdom

Site Status

GSK Investigational Site

Torquay, , United Kingdom

Site Status

GSK Investigational Site

Wakefield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

103500

Identifier Type: -

Identifier Source: org_study_id